Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, GeneDx Holdings Corp. reported revenue of $428M, up 40.0% year over year. Operating margin was -3.1% and net margin -4.9%, on a free-cash-flow margin of 3.3% with capital expenditure at 4.4% of revenue. Every figure is computed directly from WGS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $428M | -3.1% | -4.9% |
| FY2024 | $305M | -7.6% | -17.1% |
| FY2023 | $203M | -89.2% | -86.8% |
| FY2022 | $235M | -284.5% | -233.9% |
| FY2021 | $212M | -210.3% | -115.6% |
How does WGS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.